Display options
Cite
Kawaguchi T, Nakano M, Satani M, et al. Usefulness of short-term eltrombopag treatment as a supportive treatment in hepatocellular carcinoma patients with cirrhosis and severe thrombocytopenia: A report of two cases. Oncol Lett. 2014;7(6):2130-2134doi: 10.3892/ol.2014.1976.
Kawaguchi, T., Nakano, M., Satani, M., Sumie, S., Yamada, S., Amano, K., Kuromatsu, R., & Sata, M. (2014). Usefulness of short-term eltrombopag treatment as a supportive treatment in hepatocellular carcinoma patients with cirrhosis and severe thrombocytopenia: A report of two cases. Oncology letters, 7(6), 2130-2134. https://doi.org/10.3892/ol.2014.1976
Kawaguchi, Takumi, et al. "Usefulness of short-term eltrombopag treatment as a supportive treatment in hepatocellular carcinoma patients with cirrhosis and severe thrombocytopenia: A report of two cases." Oncology letters vol. 7,6 (2014): 2130-2134. doi: https://doi.org/10.3892/ol.2014.1976
Kawaguchi T, Nakano M, Satani M, Sumie S, Yamada S, Amano K, Kuromatsu R, Sata M. Usefulness of short-term eltrombopag treatment as a supportive treatment in hepatocellular carcinoma patients with cirrhosis and severe thrombocytopenia: A report of two cases. Oncol Lett. 2014 Jun;7(6):2130-2134. doi: 10.3892/ol.2014.1976. Epub 2014 Mar 14. PMID: 24932302; PMCID: PMC4049767.
Copy Download .nbib Format: NLM
Share it on

Oncol Lett. 2014 Jun;7(6):2130-2134. doi: 10.3892/ol.2014.1976. Epub 2014 Mar 14.

Usefulness of short-term eltrombopag treatment as a supportive treatment in hepatocellular carcinoma patients with cirrhosis and severe thrombocytopenia: A report of two cases.

Oncology letters

Takumi Kawaguchi, Masahito Nakano, Manabu Satani, Shuji Sumie, Shingo Yamada, Keisuke Amano, Ryoko Kuromatsu, Michio Sata

Affiliations

  1. Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan ; Department of Digestive Disease Information and Research, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan.
  2. Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan.

PMID: 24932302 PMCID: PMC4049767 DOI: 10.3892/ol.2014.1976

Abstract

Eltrombopag is an oral thrombopoietin (TPO) receptor agonist that increases platelet counts in patients with idiopathic thrombocytopenic purpura and in patients with liver cirrhosis. When cirrhotic patients with thrombocytopenia undergo elective invasive procedures, eltrombopag treatment reduces the requirement for platelet transfusions. However, TPO is known to have proliferative effects on hepatic progenitor cells and hepatic sinusoidal endothelial cells, which indicates that eltrombopag may accelerate tumor progression. Thus, the effect of eltrombopag on hepatocellular carcinoma (HCC) progression is an important issue. The current study describes two cases of HCC with cirrhosis-related thrombocytopenia. A two-week administration of eltrombopag increased platelet counts from 4.8 to 11.3×10

Keywords: chronic liver disease; growth; hepatoma; megakaryocyte growth and development factor; thrombopoietin receptor

References

  1. Hepatology. 2006 Jul;44(1):53-61 - PubMed
  2. J Gastroenterol. 2012 Dec;47(12):1342-51 - PubMed
  3. N Engl J Med. 2007 Nov 29;357(22):2227-36 - PubMed
  4. Cancer Res. 1995 Aug 15;55(16):3509-12 - PubMed
  5. BMC Cancer. 2013 Mar 16;13:121 - PubMed
  6. Eur J Gastroenterol Hepatol. 2008 Mar;20(3):209-16 - PubMed
  7. Hepatol Res. 2013 Jun;43(6):610-20 - PubMed
  8. N Engl J Med. 2007 Nov 29;357(22):2237-47 - PubMed
  9. N Engl J Med. 2012 Aug 23;367(8):716-24 - PubMed
  10. Blood. 1998 Feb 1;91(3):923-9 - PubMed
  11. Kurume Med J. 2009;56(1-2):9-15 - PubMed
  12. N Engl J Med. 2012 Nov 22;367(21):2056 - PubMed
  13. Thromb Haemost. 2013 Apr;109(4):676-83 - PubMed
  14. Liver Int. 2011 Nov;31(10):1533-40 - PubMed
  15. J Hepatol. 2008 Jun;48(6):1000-7 - PubMed

Publication Types